Quoin Pharmaceuticals Provides Corporate Update and

Company completed a public offering for aggregate gross proceeds of $16.8 millionMajority of clinical sites now open in clinical study to evaluate QRX003...

Related Keywords

Uquoin ,New Zealand General ,New Zealand ,Australia ,Taiwan ,United States ,Hong Kong ,China ,Canada ,Turkey ,America ,Michael Myers ,Endo International Plc ,Linkedin ,Paladin Labs Inc ,Queensland University Of Technology ,Quoin Pharmaceuticals Ltd ,Nasdaq ,Company Or Quoin ,Company Form ,Exchange Commission ,Company Annual Report On Form ,Endo Ventures Ltd ,European Medicines Agency ,Quoin Pharmaceuticals ,Netherton Syndrome ,Early Access Programs ,Endo International ,Endo Ventures ,Compassionate Use ,Queensland University ,New Drug ,Scientific Advice ,Distribution Agreement ,Paladin Labs ,Middle East ,Eastern Europe ,Peeling Skin Syndrome ,Palmoplantar Keratoderma ,Epidermolysis Bullosa ,Private Securities Litigation Reform Act ,Annual Report ,Nasdaq Qnrx ,Nc ,